US Patent Application 18034037. ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS simplified abstract
Contents
ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS
Organization Name
The Regents of the University of California
Inventor(s)
Qizhi Tang of San Francisco CA (US)
Jeffrey A. Bluestone of San Francisco CA (US)
Emilie Ronin of San Francisco CA (US)
Decio L. Eizirik of Ditbeek (BE)
Nick M. Devoogdt of Eppegem (BE)
ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18034037 titled 'ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS
Simplified Explanation
- The patent application is about regulatory T cells (Tregs) that have been engineered to express a specific protein called dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). - These engineered Tregs can be used in immunotherapy treatments for autoimmune, inflammatory, and degenerative diseases. - Specifically, the Tregs expressing the anti-DPP6 CAR can be used to treat or prevent autoimmune diseases affecting the pancreas or central nervous system. - The innovation involves using genetically modified Tregs to target specific proteins involved in autoimmune diseases, potentially providing a more targeted and effective treatment option. - The patent application suggests that this approach could be beneficial for patients with autoimmune diseases of the pancreas or central nervous system.
Original Abstract Submitted
The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.
